Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

ACP-501

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

AstraZeneca’s Calquence granted FDA approval in untreated mantle cell lymphoma

More than 27,500 people worldwide are affected by the rare form of non-Hodgkin lymphoma

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE to treat advanced breast cancer

BRCA1 and BRCA2 mutations are responsible for 52% and 32% of hereditary breast cancer cases, respectively

- PMLiVE

AstraZeneca’s Tagrisso granted EC approval in EGFR-mutated lung cancer

More than 450,000 people are diagnosed with lung cancer each year in Europe

- PMLiVE

AstraZeneca’s Imfinzi granted FDA approval in limited-stage small cell lung cancer

Small cell lung cancer accounts for approximately 15% of all lung cancer diagnoses

- PMLiVE

ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

The research could pave the way for the development of new drugs that prevent drug resistance

- PMLiVE

AstraZeneca appoints Iskra Reic as executive vice president international

Reic has been serving as executive vice president of the company's vaccines and immune therapies unit

- PMLiVE

UK researchers uncover first new asthma and COPD attack treatment in 50 years

The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

- PMLiVE

AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

More than 52,000 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

AstraZeneca announces $3.5bn US investment to boost research and manufacturing

The commitment is part of the company’s ambition to achieve $80bn in total revenue by 2030

- PMLiVE

Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn

The companies will advance therapeutics for undisclosed targets in Novartis’ core areas

- PMLiVE

AstraZeneca/Merck’s Koselugo shows promise in adults with neurofibromatosis type 1

The rare genetic condition affects an estimated 1.7 million people globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links